In Depth 20 Sep 2024
Mitigating hot flashes: new therapies for menopause on the rise
New therapies could address menopause symptoms, a field in which many treatment gaps still exist.
menopause
- Latest Posts
News and Trends 15 May 2023
New menopause drug gets FDA approval
The U.S. Food and Drug Administration has approved Astellas Pharma’s Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Astellas Pharma US, Inc.’s Veozah is the first neurokinin 3 (NK3) receptor antagonist approved by the FDA to treat moderate to severe hot flashes from […]
News and Trends 14 Mar 2023
Astellas menopause study meets endpoints but leukemia drug disappoints
There was good and bad news this week from Japanese company Astellas Pharma Inc. as one of its trials yielded positive results, while another didn’t meet its endpoints. Astellas Pharma announced pivotal phase 3 results for its study of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor […]
News and Trends 30 Sep 2022
Treatment for hot flushes and night sweats accepted for regulatory review by EMA
A treatment for moderate to severe vasomotor symptoms (VMS) has been accepted by the European Medicines Agency (EMA) for regulatory review. Astellas Pharma Inc., submitted a marketing authorization application (MAA) for fezolinetant, an investigational oral, nonhormonal compound. VMS is characterized by hot flushes and/or night sweats which are common menopausal symptoms. Hot flushes The news […]
News and Trends 5 Sep 2022
Astellas ‘encouraged’ by menopause symptom treatment results in China
Astellas Pharma Inc. has announced topline results from its phase 3 MOONLIGHT 3 clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, characterized by hot flashes and/or night […]
More News! 24 Jun 2022
Gurnet Point Capital and Patient Square Capital buy Radius Health for $890M
Global pharmaceutical company, Radius Health Inc, announced this week (June 23) that it has entered into a definitive agreement to be bought out by Gurnet Point Capital and Patient Square Capital in a transaction valued at approximately $890 million. Radius Health is a company focused on addressing unmet medical needs in the areas of bone […]
ADVERTISEMENT